hwapatient.blogg.se

Variant detection in cell-free DNA from NSCLC using NGS Mickey Williams, PhD, Director, Molecular Characterization Laboratory, National Cancer Institute at Frederickĭiscover potentially predictive immuno-oncology biomarkers using next-gen sequencingįiona Hyland, Director of Bioinformatics R&D, Thermo Fisher ScientificĬarl Morrison MD, DVM, Professor of Pathology at Roswell Park Cancer Institute President of OmniSeq Precision Medicine Technology

Timothy Triche, MD, PhD Co-Director, Center for Personalized Medicine Program Professor of Pathology and Pediatrics, USC Keck School of Medicine Children's Hospital Los Angeles Center for Personalized Medicine The journey to realizing the promise of precision medicine Investigating the Genetics of Human Macrophage Response and Resistance to Mycobacterium tuberculosis with AmpliSeq Gene Expression PanelsĪudrey Papp, B.S., MT ASCP(H), CLSp MB, Technical Director, The Ohio State University Jody McIntyre, Associate Director, Oncology Product Management, Thermo Fisher Scientific Navid Sadri, Clinical Assistant Professor, Pathology, University Hospitals Cleveland Medical Centerĭr. Latest advances in tumor genomic profiling for challenging samplesĭr. Liya Xu, PhD, Postdoctoral Scholar, Kuhn/Hicks Laboratory, USC Michelson Center for Convergent Bioscience

Karl Kashofer, Head of the Laboratory for Diagnostic Genome Analysis, Department of Pathology, Medical University of Grazįrom qualitative to quantitative: experiences with a cfDNA assay in metastatic breast cancer Rare allele detection in FFPE and cfDNA pathology research samplesĭr. Hans Atli Dahl, Co-founder & Chief Technology Officer, Amplexa Genetics Timothy Looney, Staff Scientist, Bioinformatics, at Thermo Fisher ScientificĪdvances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Researchĭr.

Jose Luis Costa, Affiliate Researcher, IPATIMUP and Andy Felton, Vice President of Marketing and Product Management, Clinical Next Generation Sequencing, Thermo Fisher ScientificĪdvancing precision immunotherapy through next-generation sequencing of T cell receptors, Parts I and IIĭr.

Next-Generation Solution for Genomic Profilingĭr.